Triple-Gene Presented Preliminary Phase 1 Trial Data of Investigational Multigenic Therapeutic Candidate INXN‑4001 for Treatment of Heart Failure at American Heart Association Annual Meeting
- Monday, November 18, 2019, 7:38
- PR Newswire
- Add a comment
GERMANTOWN, Md., Nov. 18, 2019 /PRNewswire/ — Triple-Gene LLC, a clinical stage cardiovascular gene therapy company and majority owned subsidiary of Intrexon Corporation (NASDAQ: XON), yesterday presented preliminary data from the Phase I trial (clinical trial identifier: NCT03409627) of…
About the Author
admin has written 20655 stories on this site.